



Cite this: *Chem. Commun.*, 2023, **59**, 3957

Subcellular localization of DNA nanodevices and their applications

Xia Liu,^{†,ad} Shuting Cao,^{†,ad} Yue Gao,^{ad} Shihua Luo,^c Ying Zhu^{abd} and Lihua Wang  ^{abd}

Received 7th November 2022,
Accepted 27th February 2023

DOI: 10.1039/d2cc06017e

rsc.li/chemcomm

The application of nanodevices based on DNA self-assembly in the field of cell biology has made significant progress in the past decade. In this study, the development of DNA nanotechnology is briefly reviewed. The subcellular localization of DNA nanodevices, and their new progress and applications in the fields of biological detection, subcellular and organ pathology, biological imaging, and other fields are reviewed. The future of subcellular localization and biological applications of DNA nanodevices is also discussed.

Introduction

Deoxyribonucleic acid (DNA), as the genetic material in life, has natural biocompatibility. In 1953, Watson of the United States and Crick of the United Kingdom successfully predicted the molecular model of the double helix structure of DNA using X-ray crystal diffraction.¹ The development of this model, arguably one of the greatest discoveries of the 20th century, made the subsequent development of DNA nanotechnology possible. Later, the Watson-Crick base-complementary pairing principle that DNA molecules follow was proposed, making the double-stranded DNA (dsDNA) structure somewhat rigid and predictable at the nano-scale. In 1982, Professor Seeman of New York University first proposed that DNA can form specific structures by the principle of base complementary pairing, and that individual structures can form complex two-dimensional (2D) or three-dimensional (3D) structures through sticky ends.² This principle is at the heart of DNA nanotechnology. Since then, DNA molecules have attracted considerable attention in the field of nanoscience, and researchers have designed and synthesized various functional DNA structures. DNA nanotechnology has been applied in various life science fields, such as tissue regeneration, disease prevention, inflammation inhibition, bio-imaging, biosensors, diagnosis, and anti-tumor drug delivery and treatment.^{3–7}

Among DNA nanostructures, functional nucleic acids are a class of DNA structures that can undergo conformational changes after binding or interacting with target analytes, which are often used in biosensor design.^{8,9} For example, in 1990, Gold and Szostak introduced the Systematic Evolution of Ligands by Exponential Enrichment (SELEX) *in vitro* screening.¹⁰ This technique can be used to screen for aptamers,¹¹ which are single-stranded DNA (ssDNA) structures that specifically bind to metal ions, adenosine triphosphate, nucleic acids, and biomacromolecules.^{12–15} DNAzymes are another class of functional nucleic acids capable of specifically cutting DNA/RNA substrates in the presence of cofactors. To date, Pb^{2+} , Zn^{2+} , Ca^{2+} , and histidine-dependent DNAzymes have been obtained through advanced *in vitro* screening.^{16,17} In addition, structures containing $\text{T}-\text{Hg}^{2+}-\text{T}$ or $\text{C}-\text{Ag}^{+}-\text{C}$ are also commonly used for Hg^{2+} and Ag^{+} sensor detection.^{18,19} In addition to functional nucleic acids that can directly and specifically bind to the target analyte, there is also a category of DNA-responsive devices with environmental specificity. Such DNA nanodevices tend to undergo conformational transformation under specific circumstances, for example, DNA nanostructures with specific sequences can form triplex^{20–23} or i-motif^{24,25} for pH sensing under an acidic environment. G-quadruplex can be used for K^{+} or Na^{+} sensing.²⁶ DNA nanostructures show great promise in biomedical applications.

Compared to that of traditional biological macromolecules, DNA has excellent programmability and can be designed more accurately according to the principle of base complementary pairing. Diverse DNA nanostructures, including 2D and complex 3D structures, can be constructed using bottom-up or top-down methods.^{27–29} Both DNA and cell membranes are electronegative. When they come into contact, it is difficult for DNA to cross the cell membrane and enter the cell matrix due to electrostatic repulsion. In contrast to single-stranded DNA (ssDNA), a variety of 2D and 3D DNA nanostructures can be

^a Division of Physical Biology, CAS Key Laboratory of Interfacial Physics and Technology, Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai 201800, China. E-mail: wanglh@sari.ac.cn

^b The Interdisciplinary Research Center, Shanghai Synchrotron Radiation Facility, Zhangjiang Laboratory, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai 201210, China

^c Department of Traumatology, Rui Jin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200025, China

^d University of Chinese Academy of Sciences, Beijing 100049, China

† These authors contributed equally to this work.

actively taken up by cells and localized into organelles without the help of transfection reagents. For example, a previous study prepared ssDNA of 55 nt in length by simple thermal annealing in order to produce DNA tetrahedra. After cell incubation, it was transported into lysosomes *via* the caveolin-mediated endocytic pathway³⁰ and could be used for the detection of the lysosomal microenvironment and lysosomal pathological studies.^{31–33} In addition, DNA nanostructures are addressable and can be modified with various groups possessing regular positions and valences, further endowing DNA nanostructures with new functions. Moreover, DNA nanostructures modified with targeting molecules can alter their fate in cells. For example, DNA tetrahedra modified with triphenylphosphine (TPP) can be localized in the mitochondria, and can be conveniently used for mitochondrial imaging and mitochondrial-related functional interventions, such as aerobic respiration and glycolysis.³⁴

The application of DNA nanostructures in the field of cell biology has developed rapidly over the past decade. In this study, we reviewed the subcellular localization of DNA nanodevices, that is how DNA nanostructures can target specific organelles and achieve specific physiological functions within them. In DNA nanodevices, organelle targeting, normalization, and sensing modules can be combined in a single structure with high stoichiometric purity and high yields, enabling

precise imaging and subcellular targeting in different living systems.³⁵ The modularity and control of chemometrics provided by DNA can lead to precision medicine, enabling the overlay of diagnosis and personalized treatment.³⁶ The following is a brief overview of the biological application of the DNA nanostructure according to its different subcellular localization (Fig. 1).

Lysosome

Lysosomes, which act as the garbage-disposal system of cells,³⁷ play a crucial role in regulating the homeostasis of cells and organisms.³⁸ Changes in the components of the lysosomal microenvironment (such as H^+ , Cl^- , Ca^{2+} , and various enzyme activities) are mostly related to the occurrence and development of many diseases, including autoimmune diseases, neurodegenerative diseases, cancer, and metabolic diseases.³⁹ Studies have shown that most DNA nanodevices are localized to lysosomes through specific endocytic pathways after being ingested by cells (Fig. 2(a)).³⁵

Double-stranded DNA nanodevices

One of the simplest DNA nanodevices is the dsDNA structure. Compared with the structure of ssDNA, dsDNA structures are




Fig. 1 Subcellular localization of DNA nanodevices.




Fig. 2 Bio-application of DNA nanodevices within lysosomes. (a) Schematic of the design principle of the DNA nanodevice in lysosomes. (b) Two-ion measurement (2-IM) using combination ion sensors and representative pseudocolor pH and Ca^{2+} maps of early endosomes (EE), late endosomes (LE), and lysosomes (Ly) labeled with CalipHluor_{Ly}. Reproduced from ref. 42 with permission from Springer Nature, copyright 2018. (c) Schematic of the DNA nanomachines that map the furin (Fu) and transferrin (Tf) pathways. Recycling endosomes (REs), LEs, EE/SEs, and Trans-Golgi network (TGN) are marked with Tf-I^{Tf} and I^{Fu} and their corresponding pH distributions. Reproduced from ref. 51 with permission from Springer Nature, copyright 2013.

more rigid, easier to be taken up by cells,⁴⁰ and can provide more functional binding sites. Under physiological conditions, dsDNA structures are also more resistant to nuclease degradation. Krishnan *et al.* designed a series of dsDNA nanodevices, which can be localized to lysosomes through endocytosis mediated by

the anion ligand-binding receptor (ALBR)^{41–44} or scavenger receptor.^{45,46} Modular modification can be used to accurately and directly integrate these modules with different functions into the same dsDNA nanostructure, thus attaining an accurate detection of chemical components in endocytic organelles during

lysosome maturation. In 2009, Modi *et al.* designed a dsDNA nanomachine that could independently respond to pH changes in living cells and that is also localized in lysosomes through the endocytic pathway mediated by ALBR. Fluorescence resonance energy transfer (FRET) facilitated by the i-motif in the dsDNA nanomachine was used to detect the pH range (5.8–7) in lysosomes and map the change in pH with a temporal and spatial resolution during lysosome maturation.⁴¹ Then, they modified the Cl[−] sensitive small molecule BAC at the end of the dsDNA nanostructure to construct a Cl[−] sensor, which is referred to as Clensor, in order to detect Cl[−] in lysosomes.^{43,47} In this study, Cl[−] was detected in endosomes and it was revealed that chloride plays an essential role in lysosomal functions.⁴⁴ Leung *et al.* developed a two-ion measurement (2-IM) method based on dsDNA nanostructures.⁴⁵ In this study, a Clensor module was combined with an i-motif module in order to simultaneously measure H⁺ and Cl[−] in lysosomes. This technology was able to identify lysosomal subgroups according to the correlation between H⁺ and Cl[−] concentrations by locating a single lysosome, and is of great significance to the study of lysosomal physiological function.⁴⁸ In addition, Narayanaswamy *et al.* reported another 2-IM nanomachine that can detect Ca²⁺ and H⁺ simultaneously. The nanomachine was combined with a Ca²⁺ reporter, referred to as CalipHluor, with a built-in pH reporter, which was able to monitor the change in the affinity of Ca²⁺ fluorophore in the endocytic pathway and its dissociation constant (K_d) with the pH value, so as to accurately calculate the true value of Ca²⁺ in the endocytic cavity (Fig. 2(b)).⁴²

Modified double-stranded DNA nanodevices

In the lysosomal acid chamber, more than 60 types of acid hydrolases have been found to be responsible for the degradation of proteins, nucleic acids, and other macromolecules.⁴⁹ By integrating fluorophores that are sensitive to thiol-disulfide exchange into lysosome-targeted DNA nanodevices, Dan *et al.* mapped the disulfide reduction in endocytic organelles of *Caenorhabditis elegans*.⁵⁰ This strategy provides a new method that can be used to measure a series of enzyme cleavage reactions in organelles. Compared with simple dsDNA nanodevices, modified dsDNA nanodevices can achieve lysosomal targeting of other endocytic pathways excluding ALBR and scavenger receptors. In another study, Modi *et al.* reported a strategy in which cells can take in two kinds of dsDNA nanodevices that are able to detect pH through different endocytic pathways at the same time. One of the nanodevices contained an 8 bp dsDNA sequence, which acted as the binding site of the engineered protein, thus enabling it to be located in the furin retrograde endocytic pathway.^{51–53} The other was modified with transferrin so that it could be located in the endocytic/circulation pathway of transferrin.^{51,54} Both dsDNA nanodevices could be located in endocytic organelles and could independently detect the corresponding pH (Fig. 2(c)).⁵¹ Similarly, by modifying RNA aptamers at one end of the Clensor, Saha *et al.* achieved Cl[−] imaging and detection during transferrin receptor-mediated endocytosis.⁴³ In addition, Saminathan *et al.* modified 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine for lipid

anchoring and voltage-sensitive fluorophores on dsDNA nanodevices, obtaining a change map of the membrane potential during lysosome maturation.⁴⁶

3D DNA nanodevices

Research has shown that in contrast to dsDNA nanodevices, 3D DNA nanostructures with precise morphology and size are more stable in complex biological systems and can also enter lysosomes through membrane receptor-mediated endocytosis.^{30,55,56} For example, Fan *et al.* found that weakened bands of a DNA tetrahedron could still be seen in gel electrophoresis even after 24 h of co-culturing with serum, whereas dsDNA had rapidly degraded.⁵⁷ Single-particle tracing technology has revealed that DNA tetrahedra are localized to lysosomes *via* caveolin-mediated endocytosis in HeLa cells.³⁰ Tetrahedrals combined with i-motifs can be used to detect the pH in lysosomes.^{58–60}

Tumor therapeutic

In addition to lysosomal microenvironment detection, DNA nanostructures have been used in lysosomal-related tumor therapy. Through proteomics, Cui *et al.* found that the low antigen cross-presentation efficiency of M2 tumor-associated macrophages (TAMs), which promote tumor angiogenesis and metastasis and inhibit immunity, thus promoting tumor growth, was related to the high lysosomal cysteine protease activity of TAMs.⁶¹ Given that DNA nanodevices are easily located in and easily degraded by lysosomes, can DNA nanodevices be reasonably designed to directly inhibit lysosomal activity after being endocytosed to lysosomes, so as to avoid DNA degradation? Utilizing the inherent lysosome localization properties of DNA nanodevices and exploiting their potential in lysosomes may be a better strategy for biomedical applications. Based on this, they anchored the cysteine protease inhibitor, E64, on a DNA nanodevice and injected the nanodevice into mice through the tail vein. The DNA nanodevice was preferentially internalized and located in the lysosome by TAMs through the scavenger receptor-mediated pathway, after which the cysteine protease inhibitor E64 was released, effectively inhibiting the activity of cysteine protease in the lysosome of TAMs, and improving the antigen presentation ability of TAMs. Subsequently, the DNA nanodevice was combined with the anti-cancer drug, cyclophosphamide (CTX), and displayed favorable effects in the treatment of mice with triple-negative breast cancer.^{40,61} Liu *et al.* designed a nanomachine based on rectangular DNA origami extending three different capture strands at a predetermined position. Through DNA hybridization, antigens (peptides), toll-like receptor (TLR) agonists, double-stranded RNA (dsRNA), and CpG DNA were precisely arranged on the DNA nanodevice. To protect the antigen/adjuvant from interference by extracellular ribonucleic acid, a DNA strand was added to the edge of the rectangle to lock it and the latter was only unlocked within a specific pH range. When DNA nanovaccines enter antigen-presenting cells, they preferentially enter the lysosomes. In the acidic environment of lysosomes, the locks on the sides of the rectangle were opened, and adjuvants and antigenic peptides were exposed, which activated a strong immune




Fig. 3 Bio-application of DNA nanodevices within mitochondria. (a) Schematic of the design principle of the DNA nanodevice in mitochondria. (b) Design of the DNA nanosensor for *in situ* localization and near-infrared (NIR)-light-activatable imaging of apurinic/apyrimidinic endonuclease 1 (APE1) in mitochondria. Reproduced from ref. 76 with permission from Wiley, copyright 2021. (c) Dynamic assembly of TDNs-G-TPP in living cells for mitochondrial interference and the consequent regulations on cellular behaviors. Reproduced from ref. 34 with permission from American Chemical Society, copyright 2022. (d) Illustration of the RFDN assembled by hybridization chain reaction, and ATP detection *in vitro* and *in vivo*. Reproduced from ref. 83 with permission from American Chemical Society, copyright 2021. (e) Schematic design of mitochondria-targeted 3KLA-TDNs/DOX for the enhancement of anti-breast cancer therapy. Reproduced from ref. 89 with permission from The Royal Society of Chemistry, copyright 2020.

response, effectively eliminating the tumor in mice and protecting mice from subsequent tumors.⁶² Gu *et al.* designed tetrahedral DNA nanostructures (TDNs) loaded with gold nanoparticles (GNPs) and doxorubicin (DOX) to treat tumors. Initially, large nanoparticles accumulated in tumors. When the pH of the tumor microenvironment was approximately 6.5, the junction of TDNs and GNP was transformed into a triple structure, resulting in the separation of TDNs and GNPs. When endocytosed into cells, TDNs formed an i-motif in order to release DOX into lysosomes at pH 5.0, thus displaying a favored anti-tumor effect.⁶³ Dong *et al.* designed a proton-driven DNA framework using the i-motif. Under the acidic environment of the lysosome, the DNA framework dynamically assembled into aggregates and remained in the lysosome. Meanwhile, the protonation effect led to a decrease in lysosomal acidity and hydrolase activity, which hindered the degradation of nucleic acid drugs in the lysosome and improved the efficiency of gene silencing. This lysosomal interference method may play a prominent role in protecting nucleic acid cargo.⁶⁴

In summary, dsDNA nanodevices can directly locate lysosomes through ALBR or scavenger receptor-mediated endocytosis pathways, and the sensor detection of these two pathways can be realized by designing suitable dsDNA nanodevices. Lysosomal sensing of other endocytic pathways, such as transferrin-mediated endocytic pathways, can be achieved by modifying other targeted groups on dsDNA. 3D DNA nanodevices, such as DNA tetrahedra, are increasingly used to intervene in lysosome microenvironments because of their more accurate morphology and size, and more stable structure under physiological conditions. Based on the characteristic that DNA nanodevices are usually endocytosed into lysosomes, the functional intervention of lysosomes is realized. By designing pH-responsive DNA nanodevices through the low pH in lysosomes, the controlled release of anti-tumor drugs is accomplished and the powerful tumor therapeutic effect is also demonstrated.

Mitochondria

Mitochondria play important roles in the production of adenosine triphosphate (ATP), reactive oxygen species (ROS), and cell apoptosis.⁶⁵ Mitochondrial abnormalities often contribute to a variety of diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.^{66–70} Therefore, mitochondria have long been considered ideal subcellular targets for cancer treatment. Because of the proton pump in the process of mitochondrial oxidative respiration, a large amount of negative charge is generated in the mitochondrial matrix. After lipophilic cations enter the cell, they can actively target the mitochondria by taking advantage of its high membrane potential. Therefore, most DNA nanodevices targeted by mitochondria are achieved by modifying lipophilic cationic ligands (Fig. 3(a)).

Mitochondrial targeting with TPP modification

DNA nanostructures can be selectively localized to mitochondria after modification with triphenylphosphine (TPP). TPP,

which contains lipophilic cations, is the most widely used mitochondrial localization group.^{71–75} TPP contains three lipophilic phenyl groups with a positive charge, which can quickly penetrate the mitochondrial membrane through to the mitochondrial matrix. Recently, Shao *et al.* designed organelle-specific, light-activated DNA nanosensors by assembling mitochondria-targeted TPP on lanthanide-doped up-conversion nanoparticles modified with DNA probes.⁷⁶ Under ultraviolet light stimulation, the P-strand, which contained a photocleavable (PC) linker of dsDNA, underwent photolysis to form the loop structure of the molecular beacon. At this time, the fluorophore and quencher modified at the adjacent ends of DNA were in proximity, resulting in quenched fluorescence. In the presence of human apurinic/apyrimidinic endonuclease 1 (APE1, a marker of malignant tumors, inhibition of which can significantly kill tumor cells),⁷⁷ the apurinic/apyrimidinic (AP) site of the molecular beacon was enzymatically hydrolyzed and the quencher was cut off, resulting in the recovery of the fluorescence signal. This sensor could achieve accurate APE1 imaging activated by “on-demand” remote light in mitochondria and improve subcellular resolution (Fig. 3(b)). Using similar DNA nanostructures, Zhao *et al.* also developed a near-infrared (NIR) light-controlled DNA strand displacement reaction to image MicroRNAs (miRNAs) in the mitochondria of living cells.^{78,79} This method is expected to be further used in the study of physiological events related to miRNAs in the mitochondria. In addition, Chai *et al.* designed redox-activated aptamer sensors that assembled redox-responsive ATP aptamer probes on cationic polymer-coated nanoparticles, which were further modified with TPP to achieve spatially controlled and gated imaging of ATP and glutathione (GSH) in the mitochondria.⁸⁰ Liu *et al.* modified TPP at one vertex of a DNA tetrahedron, and a Ca^{2+} fluorescence probe, a pH fluorescence probe, and an internal reference probe at the other three vertices to construct a mitochondrially targeted DNA nanodevice, achieving simultaneous imaging as well as biological sensing of pH and Ca^{2+} in mitochondria.⁸¹ Li *et al.* modified TPP at one vertex of a DNA tetrahedron, and designed a guanine-rich DNA sequence at the remaining three vertices to form a stable G-quadruplex structure among multiple tetrahedral frames under the trigger of a high concentration of potassium ions (~ 140 mM) in the cytoplasm, to allow the DNA tetrahedron to aggregate on the mitochondrial surface and form an anion barrier. Thus, such a nanodevice significantly inhibits aerobic respiration and glycolysis in mitochondria, reduces the production of intracellular ATP, and inhibits the migration of cancer cells (Fig. 3(c)).³⁴

Mitochondrial targeting with Cy modification

In addition to TPP modification, DNA nanodevices that modify themselves to be fat-soluble and positively charged fluorescent dyes (such as cyanine) can also efficiently accumulate in mitochondria. Such modified DNA nanodevices which can not only serve as reporting ligands, but can also achieve mitochondrial targeting, have attracted a significant amount of attention. Liu *et al.* combined cyanine dyes with a Y-shaped acid aptamer to achieve sensing and imaging of ATP in the mitochondria of living cells.⁸² Luo *et al.* hybridized two hairpin

DNA strands (HS1-Cy3 and HS2-Cy5) containing multiple ATP aptamer fragments. When ATP combined with the aptamer fragments on the DNA double-strand, the distance between Cy3 and Cy5 was shortened and a FRET signal was generated, resulting in ratio imaging of ATP in the mitochondria (Fig. 3(d)).⁸³ Jiang *et al.* designed a DNA-based “nanotrain” drug delivery system with DNA as the basic unit, cyanine dye (self-luminescence and mitochondrial targeting) as the locomotive, and the chemotherapeutic drug DOX, which could be inserted into the CG sequence of the DNA. Cy5.5 produces weak ROS under NIR light irradiation conditions, thus enhancing the sensitivity of tumor cells to traditional chemotherapy drugs and enhancing the effect of chemotherapy drugs to a certain extent.⁸⁴

Mitochondrial targeting with MTS modification

Mitochondrial targeting sequence (MTS) peptides are recognized by receptors on the mitochondrial surface, which are composed of 20–40 amino acids.⁸⁵ D-(KLAKLAK)₂ (KLA) is a positively charged specific mitochondrial-targeting sequence that can destroy the mitochondrial membrane and initiate apoptosis.^{86–88} Efficient mitochondrial targeting is achieved by modifying KLA on DNA nanodevices. Yan *et al.* modified the precise amount of KLA peptide in a DNA tetrahedron carrying DOX, which enhanced the anti-cancer effect *in vitro* by activating the mitochondrial-mediated programmed apoptotic pathway (Fig. 3(e)).⁸⁹ Abnous *et al.* designed a simple DNA nanostructure composed of two sequences: one containing ATP and the AS1411 aptamer and the other containing antimiR-21. By modifying the KLA peptide, the structure achieved the delivery of antimiR-21 and effectively inhibited tumor growth *in vitro* and *in vivo*.⁹⁰

DNA nanodevices cannot usually be used to directly target mitochondria. Specific mitochondrial targeting molecules need to be modified on DNA nanodevices, such as the lipophilic cationic ligands or mitochondrial targeting sequences mentioned earlier. Compared with other nanomaterials modifying targeted molecules, DNA nanostructures have higher biocompatibility and safety. Moreover, DNA nanostructures are programmable, and can precisely control modification sites and quantities of targeted molecules, making DNA nanodevices convenient for scientists to manipulate.

Other organelles

Nuclear targeting

The nucleus is the control center of the cell and contains the majority of the cell’s genetic material, playing an important role in cell metabolism, growth, and differentiation. Targeted intervention in the nucleus can directly induce apoptosis and effectively treat various diseases. Nucleolin is highly expressed on the surface of many types of tumor cells and is associated with the neovascularization of endothelial cells. The nucleic acid aptamer, AS1411, can specifically bind to nucleolin, preventing DNA damage repair, promoting cell apoptosis, and delivering drugs from the cell surface to the nucleus in order

to actively target the nucleus for therapy.^{91,92} However, AS1411 is ssDNA, which has a low uptake efficiency in cells and poor stability *in vivo*. Therefore, AS1411 is often modified on DNA nanodevices to improve stability and achieve nuclear targeting and therapy. Li *et al.* modified AS1411 on DNA tetrahedra and were able to specifically inhibit tumor cell growth compared to DNA tetrahedra alone.⁹³ Modification of the nuclear localization signal (NLS) on DNA nanostructures is also a commonly used method to guide foreign materials into the nucleus.⁹⁴ Liang *et al.* modified the NLS on DNA tetrahedra, which initially targeted lysosomes, to target the nuclei (Fig. 4(b)).³⁰ Furthermore, Zhao *et al.* studied the efficiency of the connection between the NLS of different lengths and DNA tetrahedra. They found that both the long NLS (NLS₂₉) and the original NLS₁₂ could target the nucleus; however, the connection efficiency between the lengthened NLS and DNA tetrahedra was higher.⁹⁵ Yang *et al.* modified the DNA tetrahedron with NLS in order to assist antisense oligonucleotides with the transfer to the nucleus after interacting with A549 cells, thus downregulating target mRNA in the nucleus and cytoplasm.⁹⁶ Similar to the function of NLS, TAT is a nuclear-localized polypeptide that promotes the aggregation of nanomaterials in the nucleus by binding to the import receptors, importin α and β , and targeting the nuclear pore complex.⁹⁷ Shao *et al.* introduced a TAT peptide on the surface of a DNA nanosensor in order to obtain APE1 imaging in the nucleus.⁷⁶

Phagosomes targeting

Phagosomes are common subcellular structures of the immune system, and pathogens that invade host cells are captured by phagosomes.^{98,99} Lysosomes can combine with phagosomes to form phagolysosomes, which transport destructive hydrolases in lysosomes to phagosomes,¹⁰⁰ and produce large amounts of ROS and reactive nitrogen in order to induce the elimination and degradation of pathogens.¹⁰¹ Phagosomes can be marked by swallowing zymosan particles. Zymosan is a boiled, trypsin-treated preparation of the cell wall of *Saccharomyces cerevisiae*.¹⁰² DNA nanodevices can be modified onto zymosan particles to target phagosomes. Myeloperoxidase (MPO) is a destructive enzyme transported to the phagosome and is the only enzyme that catalyzes the reaction of hydrogen peroxide and chloride ions to produce HOCl (a bactericide).^{103,104} Therefore, MPO activity can be determined through the detection of HOCl. When MPO activity is unbalanced, it leads to various immune-mediated inflammatory diseases.^{105,106} Thekkan *et al.*¹⁰⁷ developed a DNA-based reporter group to simultaneously quantify HOCl and pH in phagosomes by integrating HOCl-sensitive fluorophores, pH-sensitive fluorophores, reference fluorophores, and phagosome targeting groups, thus helping us to better understand the role of MPO in immune-mediated inflammatory diseases (Fig. 4(c)).¹⁰⁸ Nitric oxide synthase 2 (NOS2) is primarily found in immune cells. When pathogens are phagocytosed into the phagosomes of immune cells, the pathogen-associated molecular patterns (PAMPs) of some pathogens are recognized by TLRs that activate NOS2 and produce a large amount of nitric oxide (NO) to clear pathogens.^{109–111}




Fig. 4 Bio-application of DNA nanodevices within other organelles. (a) Schematic of the design principle of the DNA nanodevice in other organelles. (b) The structure of the DNA tetrahedron modified by NLS is used to target the nucleus. Reproduced from ref. 30 with permission from Wiley, copyright 2014. (c) Design of HOCl sensors that target phagosomes. Reproduced from ref. 107 with permission from Springer Nature, copyright 2018. (d) Two DNA nanodevices for targeting the TGN and the plasma membrane. Reproduced from ref. 115 with permission from Springer Nature, copyright 2020.

Veetil *et al.* quantified NO in phagosomes and endosomes by modifying the targeting group “Fn” sequence (a functional DNA or RNA sequence that recognizes PAMP) on DNA nanodevices. Altered PAMPs can also be used to detect NO in the phagosomes of different species (live zebrafish brain microglia), and reflects NOS2 activity.¹¹²

Golgi apparatus targeting

The Golgi apparatus consists of many flattened vesicles, which are mainly responsible for biosynthesis, secretion, and intracellular signal transduction.¹¹³ Recent studies have shown that the Golgi apparatus plays an important role in the cytoskeleton,

and in the regulation of calcium homeostasis and mitosis.¹¹⁴ However, at present, there are few researches conducted on DNA nanodevices for Golgi apparatus targeting. Jani *et al.* designed a DNA nanodevice called NOckout, which integrated NO-sensitive fluorophores, internal reference fluorophores, and plasma membrane targeting (modified with cholesterol) or Trans-Golgi network (TGN)-targeting groups (modified with MUC1 aptamer, which was combined with the low glycosylated MUC1 protein on the cancer cell cytoplasm membrane and could label the lumen of TGN through retrograde endocytosis) (Fig. 4(d)). By monitoring the production of NO in these two subcellular structures, they found that although NOS3 activity

on the TGN was ten times lower than that on the plasma membrane, it was essential in maintaining the structural integrity of the Golgi apparatus.¹¹⁵

To summarize, when DNA nanodevices are used for targeting other subcellular structures, the corresponding targeting module also needs to be modified. However, there are few studies on DNA nanodevices used for targeting phagosomes and Golgi apparatus at present. This may be because the localization mechanism for these organelles is not well understood. On the other hand, there may be technical difficulties in binding existing targeted groups to DNA nanodevices. Further enriching the DNA nanodevices targeted by various organelles will provide a powerful tool for basic research and clinical diagnosis at the subcellular level.

Conclusions and perspectives

The morphology, activity, and chemical composition of subcellular structures reflect the metabolic state of cells. Subcellular structures have been found to play a significant role in regulating the disease microenvironment, and early therapeutic intervention at the organelle level is very important.^{37,116,117} Modulating organelle activity through precisely targeted therapies at the subcellular level provides one more option for studying and understanding disease. The precision of targeted organelles *in vivo* depends on the physiological mechanism of intracellular transport and the unique properties of the subcellular structures. Precise targeting at the organelle level using fluorescently labeled DNA nanodevices has established the value of DNA nanostructures for imaging organelles for diagnostic applications, and the same can be explored for therapeutic applications. Cracking the rules of appropriate transmission between organelles, cells, and tissues could advance the use of DNA nanodevices as diagnostic and therapeutic agents.

Herein, we have reviewed recent advances in organelle targeting based on DNA nanodevices, highlighting the biological applications of the same. Cell biology research has gone through a remarkable development path from simply monitoring and analyzing the lysosomal microenvironment using the DNA nanostructures, which are naturally localized to lysosomes, to controlling its spatial distribution and biological functions in cells through modification, and further to building intelligent nano-reactors for organelle pathology and molecular diagnosis. In contrast, although liposomes or nanoparticles can now also be designed with uniform size, composition, and surface chemical modifications, they are not molecularly the same, and this variability can limit their biocompatibility, specificity, and performance, among other things.

The programmability, modularity, and biocompatibility of DNA nanodevices make them ideal for targeting organelle-level resolution in living organisms. Although some progress has been made, there are still several problems with its wide application. Firstly, research on DNA nanodevices at the subcellular level mainly focuses on lysosomes, mitochondria, and

nuclei. The study of other organelles, such as the endoplasmic reticulum and Golgi apparatus, which are responsible for protein synthesis and processing, is still insufficient. Secondly, the detection of other components of the organelle, such as other small molecules and enzyme activity in the lysozyme, depends on chemists synthesizing novel chemical molecules corresponding to the response. Finally, although the studies reviewed in this paper show that organelle function is closely related to multiple pathways that control cell and body homeostasis, the structure and function of organelles have only been understood to some extent. The understanding of how each subcellular structure is related may merely be the tip of the iceberg, and it is necessary to ultimately investigate the function of each organelle in the context of the whole cell and organism.

In the foreseeable future, we believe that DNA nanotechnology itself will be more closely integrated with cell biology and synthetic biology, so that scientists can participate more deeply in the basic levels of cell biosensors and cell life activities through the design of DNA structures, thus revealing more details of such activities and better understanding the mechanisms of life activities.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (No. 22022410, No. 82050005), 2022 Shanghai “Science and Technology Innovation Action Plan” Fundamental Research Project (22JC1401203), and the Youth Innovation Promotion Association of CAS (grant no. 2016236).

Notes and references

- 1 J. D. Watson and F. H. Crick, *Cold Spring Harbor Symp. Quant. Biol.*, 1953, **18**, 123–131.
- 2 N. C. Seeman, *J. Theor. Biol.*, 1982, **99**, 237–247.
- 3 J. Li, C. Zheng, S. Cansiz, C. Wu, J. Xu, C. Cui, Y. Liu, W. Hou, Y. Wang, L. Zhang, I. T. Teng, H. H. Yang and W. Tan, *J. Am. Chem. Soc.*, 2015, **137**, 1412–1415.
- 4 S. Li, Q. Jiang, S. Liu, Y. Zhang, Y. Tian, C. Song, J. Wang, Y. Zou, G. J. Anderson, J. Y. Han, Y. Chang, Y. Liu, C. Zhang, L. Chen, G. Zhou, G. Nie, H. Yan, B. Ding and Y. Zhao, *Nat. Biotechnol.*, 2018, **36**, 258–264.
- 5 J. Song, K. Im, S. Hwang, J. Hur, J. Nam, G. O. Ahn, S. Hwang, S. Kim and N. Park, *Nanoscale*, 2015, **7**, 9433–9437.
- 6 Q. Yuan, Y. Wu, J. Wang, D. Q. Lu, Z. L. Zhao, T. Liu, X. B. Zhang and W. H. Tan, *Angew. Chem., Int. Ed.*, 2013, **52**, 13965–13969.
- 7 H. M. Zhang, Y. L. Ma, Y. Xie, Y. An, Y. S. Huang, Z. Zhu and C. Y. J. Yang, *Sci. Rep.*, 2015, **5**, 10099.
- 8 Y. Peng, X. Wang, Y. Xiao, L. Feng, C. Zhao, J. Ren and X. Qu, *J. Am. Chem. Soc.*, 2009, **131**, 13813–13818.
- 9 F. Li, X. Han and S. Liu, *Biosens. Bioelectron.*, 2011, **26**, 2619–2625.
- 10 C. Tuerk and L. Gold, *Science*, 1990, **249**, 505–510.
- 11 A. D. Ellington and J. W. Szostak, *Nature*, 1990, **346**, 818–822.
- 12 B. Billet, B. Chovelon, E. Fiore, F. Oukacine, M. A. Petillo, P. Faure, C. Ravelet and E. Peyrin, *Angew. Chem., Int. Ed.*, 2021, **60**, 12346–12350.

13 E. Del Grosso, G. Ragazzon, L. J. Prins and F. Ricci, *Angew. Chem., Int. Ed.*, 2019, **58**, 5582–5586.

14 M. Liu, J. Wang, Y. Chang, Q. Zhang, D. Chang, C. Y. Hui, J. D. Brennan and Y. Li, *Angew. Chem., Int. Ed.*, 2020, **59**, 7706–7710.

15 H. Qu, A. T. Csordas, J. Wang, S. S. Oh, M. S. Eisenstein and H. T. Soh, *ACS Nano*, 2016, **10**, 7558–7565.

16 X. B. Zhang, R. M. Kong and Y. Lu, *Annu. Rev. Anal. Chem.*, 2011, **4**, 105–128.

17 W. Zhou, R. Saran and J. Liu, *Chem. Rev.*, 2017, **117**, 8272–8325.

18 P. Chen, Y. Wang, Y. He, K. Huang, X. Wang, R. Zhou, T. Liu, R. Qu, J. Zhou, W. Peng, M. Li, Y. Bai, J. Chen, J. Huang, J. Geng, Y. Xie, W. Hu and B. Ying, *ACS Nano*, 2021, **15**, 11634–11643.

19 F. Gao, F. Zhan, S. Li, P. Antwi-Mensah, L. Niu and Q. Wang, *Biosens. Bioelectron.*, 2022, **209**, 114280.

20 Y. Zhou, E. Kierzek, Z. P. Loo, M. Antonio, Y. H. Yau, Y. W. Chuah, S. Geifman-Shochat, R. Kierzek and G. Chen, *Nucleic Acids Res.*, 2013, **41**, 6664–6673.

21 L. Liu, J. W. Liu, Z. M. Huang, H. Wu, N. Li, L. J. Tang and J. H. Jiang, *Anal. Chem.*, 2017, **89**, 6944–6947.

22 H. Li, X. Zhou, D. Yao and H. Liang, *Chem. Commun.*, 2018, **54**, 3520–3523.

23 Q. Tang, W. Lai, P. P. Wang, X. W. Xiong, M. S. Xiao, L. Li, C. H. Fan and H. Pei, *Angew. Chem., Int. Ed.*, 2021, **60**, 15013–15019.

24 H. L. Liu, Q. C. Jiang, J. Pang, Z. Y. Jiang, J. Cao, L. N. Ji, X. H. Xia and K. Wang, *Adv. Funct. Mater.*, 2018, **28**, 1703847.

25 M. Debnath, K. Fatma and J. Dash, *Angew. Chem., Int. Ed.*, 2019, **58**, 2942–2957.

26 M. Debnath, S. Chakraborty, Y. P. Kumar, R. Chaudhuri, B. Jana and J. Dash, *Nat. Commun.*, 2020, **11**, 469.

27 F. Zhang, J. Nangreave, Y. Liu and H. Yan, *J. Am. Chem. Soc.*, 2014, **136**, 11198–11211.

28 X. Lim, *Nature*, 2017, **546**, 687–689.

29 N. C. Seeman and H. F. Sleiman, *Nat. Rev. Mater.*, 2018, **3**, 17068.

30 L. Liang, J. Li, Q. Li, Q. Huang, J. Shi, H. Yan and C. Fan, *Angew. Chem., Int. Ed.*, 2014, **53**, 7745–7750.

31 L. He, D. Lu, H. Liang, S. Xie, X. Zhang, Q. Liu, Q. Yuan and W. Tan, *J. Am. Chem. Soc.*, 2018, **140**, 258–263.

32 A. Lacroix and H. F. Sleiman, *ACS Nano*, 2021, **15**, 3631–3645.

33 P. Peng, Y. Du, J. Zheng, H. Wang and T. Li, *Angew. Chem., Int. Ed.*, 2019, **58**, 1648–1653.

34 F. Li, Y. Liu, Y. Dong, Y. Chu, N. Song and D. Yang, *J. Am. Chem. Soc.*, 2022, **144**, 4667–4677.

35 A. Saminathan, M. Zajac, P. Anees and Y. Krishnan, *Nat. Rev. Mater.*, 2022, **7**, 355–371.

36 Y. Krishnan, J. Zou and M. S. Jani, *ACS Cent. Sci.*, 2020, **6**, 1938–1954.

37 A. Ballabio and J. S. Bonifacino, *Nat. Rev. Mol. Cell Biol.*, 2020, **21**, 101–118.

38 M. Cao, X. Luo, K. Wu and X. He, *Signal Transduction Targeted Ther.*, 2021, **6**, 379.

39 S. R. Bonam, F. Wang and S. Muller, *Nat. Rev. Drug Discovery*, 2019, **18**, 923–948.

40 J. Li and C. Fan, *Nat. Nanotechnol.*, 2021, **16**, 1306–1307.

41 S. Modi, M. G. Swetha, D. Goswami, G. D. Gupta, S. Mayor and Y. Krishnan, *Nat. Nanotechnol.*, 2009, **4**, 325–330.

42 N. Narayanaswamy, K. Chakraborty, A. Saminathan, E. Zeichner, K. Leung, J. Devany and Y. Krishnan, *Nat. Meth.*, 2019, **16**, 95–102.

43 S. Saha, V. Prakash, S. Halder, K. Chakraborty and Y. Krishnan, *Nat. Nanotechnol.*, 2015, **10**, 645–651.

44 K. Chakraborty, K. Leung and Y. Krishnan, *eLife*, 2017, **6**, e28862.

45 K. Leung, K. Chakraborty, A. Saminathan and Y. Krishnan, *Nat. Nanotechnol.*, 2019, **14**, 176–183.

46 A. Saminathan, J. Devany, A. T. Veetil, B. Suresh, K. S. Pillai, M. Schwake and Y. Krishnan, *Nat. Nanotechnol.*, 2021, **16**, 96–103.

47 V. Prakash, S. Saha, K. Chakraborty and Y. Krishnan, *Chem. Sci.*, 2016, **7**, 1946–1953.

48 A. Saminathan, V. S. Noyola and Y. Krishnan, *Trends Biochem. Sci.*, 2020, **45**, 365–366.

49 P. Saftig and J. Klumperman, *Nat. Rev. Mol. Cell Biol.*, 2009, **10**, 623–635.

50 K. Dan, A. T. Veetil, K. Chakraborty and Y. Krishnan, *Nat. Nanotechnol.*, 2019, **14**, 252–259.

51 S. Modi, C. Nizak, S. Surana, S. Halder and Y. Krishnan, *Nat. Nanotechnol.*, 2013, **8**, 459–467.

52 S. Modi, S. Halder, C. Nizak and Y. Krishnan, *Nanoscale*, 2014, **6**, 1144–1152.

53 W. G. Mallet and F. R. Maxfield, *J. Cell Biol.*, 1999, **146**, 345–359.

54 J. F. Presley, S. Mayor, K. W. Dunn, L. S. Johnson, T. E. McGraw and F. R. Maxfield, *J. Cell Biol.*, 1993, **122**, 1231–1241.

55 L. He, D. Q. Lu, H. Liang, S. Xie, C. Luo, M. Hu, L. Xu, X. Zhang and W. Tan, *ACS Nano*, 2017, **11**, 4060–4066.

56 F. Hong, F. Zhang, Y. Liu and H. Yan, *Chem. Rev.*, 2017, **117**, 12584–12640.

57 J. Li, H. Pei, B. Zhu, L. Liang, M. Wei, Y. He, N. Chen, D. Li, Q. Huang and C. Fan, *ACS Nano*, 2011, **5**, 8783–8789.

58 X. Yue, Y. Qiao, D. Gu, R. Qi, H. Zhao, Y. Yin, W. Zhao, R. Xi and M. Meng, *Anal. Chem.*, 2021, **93**, 7250–7257.

59 S. He, M. Liu, F. Yin, J. Liu, Z. Ge, F. Li, M. Li, J. Shi, L. Wang, X. Mao, X. Zuo and Q. Li, *Chem. Commun.*, 2021, **57**, 3247–3250.

60 A. Rajwar, S. R. Shetty, P. Vaswani, V. Morya, A. Barai, S. Sen, M. Sonawane and D. Bhatia, *ACS Nano*, 2022, **16**, 10496–10508.

61 C. Cui, K. Chakraborty, X. A. Tang, K. Q. Schoenfelt, A. Hoffman, A. Blank, B. McBeth, N. Pulliam, C. A. Reardon, S. A. Kulkarni, T. Vaisar, A. Ballabio, Y. Krishnan and L. Becker, *Nat. Nanotechnol.*, 2021, **16**, 1394–1402.

62 S. Liu, Q. Jiang, X. Zhao, R. Zhao, Y. Wang, Y. Wang, J. Liu, Y. Shang, S. Zhao, T. Wu, Y. Zhang, G. Nie and B. Ding, *Nat. Mater.*, 2021, **20**, 421–430.

63 D. Gu, Y. Qiao, H. Fu, H. Zhao, X. Yue, S. Wang, Y. Yin, R. Xi, X. Fu, X. Zhao and M. Meng, *ACS Appl. Mater. Interfaces*, 2022, **14**, 38048–38055.

64 Y. Dong, F. Li, Z. Lv, S. Li, M. Yuan, N. Song, J. Liu and D. Yang, *Angew. Chem., Int. Ed.*, 2022, **61**, e202207770.

65 A. T. Hoye, J. E. Davoren, P. Wipf, M. P. Fink and V. E. Kagan, *Acc. Chem. Res.*, 2008, **41**, 87–97.

66 S. S. Liew, X. Qin, J. Zhou, L. Li, W. Huang and S. Q. Yao, *Angew. Chem., Int. Ed.*, 2021, **60**, 2232–2256.

67 H. Singh, D. Sareen, J. M. George, V. Bhardwaj, S. Rha, S. J. Lee, S. Sharma, A. Sharma and J. S. Kim, *Coord. Chem. Rev.*, 2022, **452**, 214283.

68 M. J. Devine and J. T. Kittler, *Nat. Rev. Neurosci.*, 2018, **19**, 63–80.

69 F. J. Bock and S. W. G. Tait, *Nat. Rev. Mol. Cell Biol.*, 2020, **21**, 85–100.

70 M. Khacho, R. Harris and R. S. Slack, *Nat. Rev. Neurosci.*, 2019, **20**, 34–48.

71 J. Zielonka, J. Joseph, A. Sikora, M. Hardy, O. Ouari, J. Vasquez-Vivar, G. Cheng, M. Lopez and B. Kalyanaraman, *Chem. Rev.*, 2017, **117**, 10043–10120.

72 R. A. Smith, R. C. Hartley and M. P. Murphy, *Antioxid. Redox Signaling*, 2011, **15**, 3021–3038.

73 R. A. Smith, R. C. Hartley, H. M. Cocheme and M. P. Murphy, *Trends Pharmacol. Sci.*, 2012, **33**, 341–352.

74 W. Xu, Z. Zeng, J. H. Jiang, Y. T. Chang and L. Yuan, *Angew. Chem., Int. Ed.*, 2016, **55**, 13658–13699.

75 P. Lu, B. J. Bruno, M. Rabenau and C. S. Lim, *J. Controlled Release*, 2016, **240**, 38–51.

76 Y. L. Shao, J. Zhao, J. Y. Yuan, Y. L. Zhao and L. L. Li, *Angew. Chem., Int. Ed.*, 2021, **60**, 8923–8931.

77 F. Shah, D. Logsdon, R. A. Messmann, J. C. Fehrenbacher, M. L. Fishel and M. R. Kelley, *NPJ Precis. Oncol.*, 2017, **1**, 19.

78 F. Z. Yu, Y. L. Shao, X. Chai, Y. L. Zhao and L. L. Li, *Angew. Chem., Int. Ed.*, 2022, **61**, e202203238.

79 J. Zhao, Z. Li, Y. Shao, W. Hu and L. Li, *Angew. Chem., Int. Ed.*, 2021, **60**, 17937–17941.

80 X. Chai, Z. Fan, M. M. Yu, J. Zhao and L. Li, *Nano Lett.*, 2021, **21**, 10047–10053.

81 Z. Liu, H. Pei, L. Zhang and Y. Tian, *ACS Nano*, 2018, **12**, 12357–12368.

82 J. Liu, L. Yang, C. Xue, G. Huang, S. Chen, J. Zheng and R. Yang, *ACS Appl. Mater. Interfaces*, 2021, **13**, 33894–33904.

83 L. Luo, M. Wang, Y. Zhou, D. Xiang, Q. Wang, J. Huang, J. Liu, X. Yang and K. Wang, *Anal. Chem.*, 2021, **93**, 6715–6722.

84 T. Jiang, L. Zhou, H. Liu, P. Zhang, G. Liu, P. Gong, C. Li, W. Tan, J. Chen and L. Cai, *Anal. Chem.*, 2019, **91**, 6996–7000.

85 L. F. Yousif, K. M. Stewart, K. L. Horton and S. O. Kelley, *Chem-BioChem*, 2009, **10**, 2081–2088.

86 L. Agemy, D. Friedmann-Morvinski, V. R. Kotamraju, L. Roth, K. N. Sugahara, O. M. Girard, R. F. Mattrey, I. M. Verma and E. Ruoslahti, *Proc. Natl. Acad. Sci. U. S. A.*, 2011, **108**, 17450–17455.

87 J. W. Sun, L. Jiang, Y. Lin, E. M. Gerhard, X. H. Jiang, L. Li, J. Yang and Z. W. Gu, *Int. J. Nanomed.*, 2017, **12**, 1517–1537.

88 H. M. Ellerby, W. Arap, L. M. Ellerby, R. Kain, R. Andrusiak, G. D. Rio, S. Krajewski, C. R. Lombardo, R. Rao, E. Ruoslahti, D. E. Bredesen and R. Pasqualini, *Nat. Med.*, 1999, **5**, 1032–1038.

89 J. Yan, J. Chen, N. Zhang, Y. Yang, W. Zhu, L. Li and B. He, *J. Mater. Chem. B*, 2020, **8**, 492–503.

90 K. Abnous, N. M. Danesh, M. Ramezani, M. Alibolandi, A. Bahreyni, P. Lavaee, S. A. Moosavian and S. M. Taghdisi, *J. Drug Targeting*, 2020, **28**, 852–859.

91 D. H. Dam, J. H. Lee, P. N. Sisco, D. T. Co, M. Zhang, M. R. Wasielewski and T. W. Odom, *ACS Nano*, 2012, **6**, 3318–3326.

92 D. F. Wang, M. Liu, Y. S. Wu, T. X. Weng, L. Wang, Y. F. Zhang, Y. N. Zhao and J. Han, *J. Mol. Liq.*, 2022, 355, 118947.

93 Q. Li, D. Zhao, X. Shao, S. Lin, X. Xie, M. Liu, W. Ma, S. Shi and Y. Lin, *ACS Appl. Mater. Interfaces*, 2017, **9**, 36695–36701.

94 Y. C. Pan, R. Weng, L. H. Zhang, J. Qiu, X. L. Wang, G. Q. Liao, Z. H. Qin, L. P. Zhang, H. H. Xiao, Y. Z. Qian and X. Su, *Nano Today*, 2022, **46**, 101573.

95 Y. Zhao, F. Li, L. J. Guo, J. B. Dai, S. Xing and L. H. Wang, *Nucl. Technol.*, 2017, **40**, 48–53.

96 J. Yang, Q. Jiang, L. He, P. Zhan, Q. Liu, S. Liu, M. Fu, J. Liu, C. Li and B. Ding, *ACS Appl. Mater. Interfaces*, 2018, **10**, 23693–23699.

97 L. Pan, Q. He, J. Liu, Y. Chen, M. Ma, L. Zhang and J. Shi, *J. Am. Chem. Soc.*, 2012, **134**, 5722–5725.

98 L. M. Stuart and R. A. Ezekowitz, *Immunity*, 2005, **22**, 539–550.

99 L. Chernyak and A. I. Tauber, *Cell. Immunol.*, 1988, **117**, 218–233.

100 A. W. Segal, *Annu. Rev. Immunol.*, 2005, **23**, 197–223.

101 C. C. Winterbourn and A. J. Kettle, *Antioxid. Redox Signaling*, 2013, **18**, 642–660.

102 D. M. Underhill, *J. Endotoxin Res.*, 2003, **9**, 176–180.

103 S. J. Klebanoff, A. J. Kettle, H. Rosen, C. C. Winterbourn and W. M. Nauseef, *J. Leukoc. Biol.*, 2013, **93**, 185–198.

104 M. B. Hampton, A. J. Kettle and C. C. Winterbourn, *Blood*, 1998, **92**, 3007–3017.

105 P. Valadez-Cosmes, S. Raftopoulou, Z. N. Mihalic, G. Marsche and J. Kargl, *Pharmacol. Ther.*, 2022, **236**, 108052.

106 S. E. Janus, J. Hajjari, T. Chami, M. Karnib, S. G. Al-Kindi and I. Rashid, *Curr. Probl. Cardiol.*, 2021, **47**, 101080.

107 S. Thekkan, M. S. Jani, C. Cui, K. Dan, G. Zhou, L. Becker and Y. Krishnan, *Nat. Chem. Biol.*, 2019, **15**, 1165–1172.

108 P. Anees, M. Zajac and Y. Krishnan, *Methods Cell Biol.*, 2021, **164**, 119–136.

109 A. P. West, A. A. Koblansky and S. Ghosh, *Annu. Rev. Cell Dev. Biol.*, 2006, **22**, 409–437.

110 O. Takeuchi and S. Akira, *Cell*, 2010, **140**, 805–820.

111 T. H. Mogensen, *Clin. Microbiol. Rev.*, 2009, **22**, 240–273.

112 A. T. Veetil, J. Zou, K. W. Henderson, M. S. Jani, S. M. Shaik, S. S. Sisodia, M. E. Hale and Y. Krishnan, *Proc. Natl. Acad. Sci. U. S. A.*, 2020, **117**, 14694–14702.

113 R. S. Li, C. Wen, C. Z. Huang and N. Li, *Trends Anal. Chem.*, 2022, **156**, 116714.

114 G. Guizzanti and J. Seemann, *Proc. Natl. Acad. Sci. U. S. A.*, 2016, **113**, E6590–E6599.

115 M. S. Jani, J. Zou, A. T. Veetil and Y. Krishnan, *Nat. Chem. Biol.*, 2020, **16**, 660–666.

116 N. Zheng, Q. Wang, S. Zhang, C. Mao, L. He and S. Liu, *J. Mater. Chem. B*, 2022, **10**, 7450–7459.

117 M. Zhang, N. Xu, W. Xu, G. Ling and P. Zhang, *Pharmacol. Res.*, 2022, **175**, 105861.